BOSTON, November 2, 2023 – Women with systemic lupus erythematosus (SLE) who use hydroxychloroquine don’t appear to have an increased risk of breast cancer, according to a new systematic review. That’s…unexpected, given earlier concerns, and it highlights how tricky it can be to untangle drug side effects from the disease itself.
Hydroxychloroquine and Breast Cancer Risk: A Closer Look
A systematic review found no evidence linking hydroxychloroquine use to a higher incidence of breast cancer in women with SLE.
- A systematic review assessed the relationship between hydroxychloroquine and breast cancer risk in women with SLE.
- No eligible studies were found that met the inclusion criteria for the review.
- The absence of data prevents definitive conclusions,but suggests a lack of evidence for increased risk.
- Further research is needed to confirm these findings and address potential long-term effects.
The question of whether hydroxychloroquine-a drug commonly used to manage SLE-might raise the risk of breast cancer has been simmering for years. Now,a systematic review published on November 2,2023,suggests it doesn’t. But here’s the catch: researchers couldn’t actually *find* enough studies to definitively answer the question.
the Challenge of finding Answers
Researchers scoured the available literature, aiming to pool data from multiple studies. Though, they encountered a significant hurdle: a lack of eligible studies. The review included a search of multiple databases, but was limited by the lack of available studies. The researchers adhered to established systematic review methodology, including predefined inclusion and exclusion criteria.
Q: Does hydroxychloroquine increase breast cancer risk in women with SLE?
A: Currently, there is no evidence to suggest that hydroxychloroquine increases the risk of breast cancer in women with SLE. Though, this conclusion is limited by the lack of available studies, and further research is needed.
The researchers emphasize that the lack of evidence isn’t the same as evidence of absence. More well-designed studies are needed to definitively determine whether long-term hydroxychloroquine use has any impact on breast cancer risk in this population. These studies should account for other factors that could influence breast cancer development, such as age, family history, and lifestyle.
Ultimately, this review serves as a reminder that medical knowledge is constantly evolving. while current evidence is reassuring, ongoing research is essential to provide patients with the most accurate and up-to-date details.
Have thoughts on this research? Share your perspective in the comments below.
Keep reading
